Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.

EClinicalMedicine · 2023 · PMC10167478 · PMID 37193346

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

found that lung virus titer reductions in molnupiravir-treated males were highly significant compared to vehicle-treated males, but not in molnupiravir-treated females. 22 However, the potential mechanism by which male patients with COVID-19 and benefit better from Azvudine requires further investigation.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.